Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 3 Adverse events

From: Azithromycin in severe malaria bacterial co-infection in African children (TABS-PKPD): a phase II randomised controlled trial

 

10 mg/kg

15 mg/kg

15 vs 10 p value

20 mg/kg

20 vs 10 p value

Control group

SAEs

 Number of children ever having an SAE

3 (9%)

3 (9%)

1.00

4 (11%)

1.00

2 (4%)

 Number of SAEs

3

3

 

4

 

2

SAE criteria

 Fatal

1 (33%)

1 (33%)

 

1 (25%)

 

0 (0%)

 Life-threatening

0 (0%)

0 (0%)

 

0 (0%)

 

0 (0%)

 Caused or prolonged hospitalisation

2 (67%)

2 (67%)

 

3 (75%)

 

2 (100%)

 Persistent or significant disability/incapacity

0 (0%)

0 (0%)

 

0 (0%)

 

0 (0%)

 Other important medical condition

0 (0%)

0 (0%)

 

0 (0%)

 

0 (0%)

  1. No further grade 3/4 AEs were reported that were not SAEs. No SAEs were judged to be related to azithromycin, the dose of azithromycin, or lead to a change in azithromycin
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us